Axim Biotech

AXIM Biotechnologies is a diagnostic-focused R&D company with a mission to improve patient lives through rapid, in-clinic testing solutions. The company has achieved commercial validation with two FDA-cleared ophthalmological diagnostics and is leveraging its integrated platform to diversify into early cancer detection and cannabinoid research. Its strategy combines direct commercialization, strategic alliances, and a client-focused diagnostic development service to address unmet needs in multiple therapeutic areas.

A vertically integrated R&D platform for developing rapid, quantitative, point-of-care lateral flow diagnostic tests, with capabilities extending to biomarker discovery, assay design, and formulation chemistry.

Competes in ocular Dx with TearLab and QuidelOrtho, differentiated by quantitative lactoferrin testing. Faces intense competition in broader POC Dx from giants like Abbott and Roche. Early IP and niche focus are key competitive advantages.